|Day Low/High||12.51 / 12.92|
|52 Wk Low/High||11.47 / 15.78|
U.K. Trust launches Allscripts Sunrise to enable integrated patient record
Investor community invited to access a live webcast during the company's annual user conference
Transaction significantly expands Allscripts client reach in U.S. hospitals and health systems and expands solutions portfolio
Healthcare organization furthers commitment to community health strategy by adding Sunrise™ solution suite
Partnership will enhance Allscripts population health, care management and patient engagement capabilities to meet growing customer demand
Investors in Allscripts Healthcare Solutions, Inc. saw new options begin trading this week, for the August 18th expiration.
New partnership to provide drug price options at point of prescribing
Allscripts Sunrise™ first acute EHR to successfully deliver certified 2015 technology; Allscripts TouchWorks® EHR achieves full certification by completing G2 Object Measure Certification
Shareholders elect biotech industry executive Mara G. Aspinall; all current Allscripts directors re-elected
The National Center for Health Statistics (NCHS), part of the CDC, to modernize National Health Care Surveys data collection process
Expanded collaboration also includes Allscripts TouchWorks EHR® and FollowMyHealth®
Since its inception in 2015, the Payer & Life Science service has saved significant time for payers and practices
Electronic health record (EHR) successfully demonstrates certified 2015 technology and automated measure calculation
Award winning interoperability solution can bring rapid value to clinicians through faster implementation and lowered costs
Looking Glass® Abstracting Workflow Enables Better Aggregation of Documentation to Support Improved Coding Processes
Here are Monday's top research calls, including an upgrade for Adobe, a downgrade for KB Home and new coverage of Starbucks and Snap.
In trading on Thursday, shares of Allscripts Healthcare Solutions, Inc. crossed above their 200 day moving average of $12.29, changing hands as high as $12.32 per share.
Momentum shows EPSi's success in empowering clients to meet rapidly changing market needs
Platform enables oncologists to identify evidence-based treatment regimens for patients through first-of-its kind integration of eviti® platform and Allscripts Sunrise™
Solution Delivers Actionable Clinical-Genomic Insights to the Point of Care to Empower Clinicians